Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Innovation is transformative. It’s why we ride in a Mustang instead of on a mustang. Centuries of knowledge now fit in the palm of our hand. Products move from reliable to revolutionary. Yet ideas ...

Java 26, due in March with structured concurrency, lazy constants, AOT object caching, and primitive types in patterns, instanceof, and switch, has entered a second rampdown phase for bug fixes. Java ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.